Methods and Compositions for Treating Cancer Using BCL-2 Antisense Oligomers, Tyrosine Kinase Inhibitors, and Chemotherapeutic Agents
Methods and compositions are provided for treating cell-proliferative related disorders such as cancer. Methods of inhibiting the growth of cancer cells comprise contacting the cancer cells with a Bcl-2 antisense oligomer; contacting the cancer cells with a tyrosine kinase inhibitor; and contacting the cancer cells with a cytotoxic chemotherapeutic agent. Methods of treating cancer in a human comprise administering to the human a Bcl-2 antisense oligomer, a tyrosine kinase inhibitor, and a cytotoxic chemotherapeutic agent. Kits containing compositions in amounts sufficient for at least one cycle of treatment comprise a triplet combination therapy of a Bcl-2 antisense oligomer, a tyrosine kinase inhibitor, and a cytotoxic chemotherapeutic agent. In selected embodiments, the tyrosine kinase inhibitor is one that targets cell surface kinase receptors, such as VEGFR (e.g., VEGFR1, VEGFR2, VEGFR3), PDGFR, KIT, and FLT-3.
1 . A method of inhibiting the growth of cancer cells comprising:
contacting the cancer cells with a Bcl-2 antisense oligomer;
contacting the cancer cells with a tyrosine kinase inhibitor; and
contacting the cancer cells with a cytotoxic chemotherapeutic agent.
2 . The method of claim 1 , wherein the Bcl-2 antisense oligomer comprises an oblimersen compound.
3 . The method of claim 1 , wherein the tyrosine kinase inhibitor targets a cell surface kinase receptor.
4 . The method of claim 3 , wherein the cell surface kinase receptor comprises a vascular endothelial growth factor receptor, a stem cell factor receptor, or an fms-like tyrosine kinase-3 receptor.
5 . The method of claim 1 , wherein the cytotoxic chemotherapeutic agent comprises dacarbazine, docetaxel, paclitaxel, cisplatin, 5-fluorouracil, doxorubicin, etoposide, cyclophosphamide, fludarabine, irinotecan, or cytosine arabinoside (Ara-C).
6 . A method of treating cancer in a human comprising administering to the human a Bcl-2 antisense oligomer, a tyrosine kinase inhibitor, and a cytotoxic chemotherapeutic agent.
7 . The method of claim 6 , wherein the Bcl-2 antisense oligomer is administered twice per week, the tyrosine kinase inhibitor is administered five times per week, and the cytotoxic chemotherapeutic agent is administered once per week.
8 . The method of claim 6 , wherein the Bcl-2 antisense oligomer comprises an oblimersen compound; the tyrosine kinase inhibitor comprises sunitinib, sorafenib, or combinations thereof; and the cytotoxic chemotherapeutic agent comprises paclitaxel.
9 . The method of claim 6 , wherein the Bcl-2 antisense oligomer is administered before the cytotoxic chemotherapeutic agent.
10 . A kit comprising a Bcl-2 antisense oligomer in an amount sufficient for at least one cycle of cancer treatment, a tyrosine kinase inhibitor in an amount sufficient for at least one cycle of cancer treatment, and a cytotoxic chemotherapeutic agent in an amount sufficient for at least one cycle of cancer treatment.
11 . The kit of claim 10 , wherein the cycle is a five-day cycle.